NUCB2 and type 2 diabetes mellitus: According to a systematic review and meta-analysis conducted by Zhai et al. [26] for the assessment of circulatory nesfatin-1 levels and T2DM, patients who were just diagnosed with the disease had higher levels of nesfatin-1, while those who were receiving antidiabetic treatment had lower levels.